59 related articles for article (PubMed ID: 18416470)
1. Repurposing lansoprazole to alleviate metabolic syndrome
Wu Y; Xin J; Li X; Yang T; Liu Y; Zhao Y; Xie W; Jiang M
Acta Pharm Sin B; 2024 Apr; 14(4):1711-1725. PubMed ID: 38572109
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia.
Maity S; Choudhury S; Hazra A; Das AK
Indian J Pharmacol; 2014; 46(5):498-502. PubMed ID: 25298578
[TBL] [Abstract][Full Text] [Related]
3. Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial.
Dewan B; Philipose N
Gastroenterol Res Pract; 2011; 2011():640685. PubMed ID: 21687618
[TBL] [Abstract][Full Text] [Related]
4. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition.
Dewan B; Chimata R
World J Gastrointest Pharmacol Ther; 2010 Oct; 1(5):112-8. PubMed ID: 21577305
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
Ohara S; Haruma K; Kinoshita Y; Kusano M
J Gastroenterol; 2010 Dec; 45(12):1219-27. PubMed ID: 20632193
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity].
Tanaka M; Banba M; Joko A; Moriyama Y
Nihon Yakurigaku Zasshi; 2001 Jun; 117(6):377-86. PubMed ID: 11436515
[TBL] [Abstract][Full Text] [Related]
7. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Satoh H
Curr Pharm Des; 2013; 19(1):67-75. PubMed ID: 22950496
[TBL] [Abstract][Full Text] [Related]
8. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
Yamagishi H; Koike T; Ohara S; Horii T; Kikuchi R; Kobayashi S; Abe Y; Iijima K; Imatani A; Suzuki K; Hishinuma T; Goto J; Shimosegawa T
World J Gastroenterol; 2008 Apr; 14(15):2406-10. PubMed ID: 18416470
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
Suzuki T; Kagami T; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Eur J Clin Pharmacol; 2018 Jan; 74(1):45-52. PubMed ID: 28986609
[TBL] [Abstract][Full Text] [Related]
10. Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.
Iida H; Inamori M; Nozaki Y; Endo H; Hosono K; Akiyama T; Sakamoto Y; Takahashi H; Koide T; Tokoro C; Abe Y; Nakajima A
BMC Gastroenterol; 2009 Jul; 9():52. PubMed ID: 19589146
[TBL] [Abstract][Full Text] [Related]
11. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.
Ikawa K; Shimatani T; Hayato S; Morikawa N; Tazuma S
Biol Pharm Bull; 2007 May; 30(5):1003-6. PubMed ID: 17473452
[TBL] [Abstract][Full Text] [Related]
13. Afferent signalling from the acid-challenged rat stomach is inhibited and gastric acid elimination is enhanced by lafutidine.
Edelsbrunner ME; Nakano M; Holzer P
BMC Gastroenterol; 2009 Jun; 9():40. PubMed ID: 19490646
[TBL] [Abstract][Full Text] [Related]
14. Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Koike T; Ohara S; Sehine H; Kawamura M; Abe Y; Inomata Y; Iijima K; Imatani A; Shimosegawa T
Hepatogastroenterology; 2007 Jun; 54(76):1280-4. PubMed ID: 17629089
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
